132 related articles for article (PubMed ID: 15169804)
1. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome.
Grigsby PW; Siegel BA; Dehdashti F; Rader J; Zoberi I
J Clin Oncol; 2004 Jun; 22(11):2167-71. PubMed ID: 15169804
[TBL] [Abstract][Full Text] [Related]
2. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.
Schwarz JK; Siegel BA; Dehdashti F; Grigsby PW
JAMA; 2007 Nov; 298(19):2289-95. PubMed ID: 18029833
[TBL] [Abstract][Full Text] [Related]
3. Posttherapy surveillance monitoring of cervical cancer by FDG-PET.
Grigsby PW; Siegel BA; Dehdashti F; Mutch DG
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):907-13. PubMed ID: 12605968
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R
Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578
[TBL] [Abstract][Full Text] [Related]
5. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2007 Oct; 110(8):1738-44. PubMed ID: 17786947
[TBL] [Abstract][Full Text] [Related]
6. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.
Grigsby PW; Siegel BA; Dehdashti F
J Clin Oncol; 2001 Sep; 19(17):3745-9. PubMed ID: 11533097
[TBL] [Abstract][Full Text] [Related]
7. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer.
Schwarz JK; Siegel BA; Dehdashti F; Grigsby PW
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):185-90. PubMed ID: 22014958
[TBL] [Abstract][Full Text] [Related]
8. Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET.
Grigsby PW; Mutch DG; Rader J; Herzog TJ; Zoberi I; Siegel BA; Dehdashti F
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):444-9. PubMed ID: 15667965
[TBL] [Abstract][Full Text] [Related]
9. Roles of posttherapy
Liu FY; Su TP; Wang CC; Chao A; Chou HH; Chang YC; Yen TC; Lai CH
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1197-1204. PubMed ID: 29470614
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy.
Nakamoto Y; Eisbruch A; Achtyes ED; Sugawara Y; Reynolds KR; Johnston CM; Wahl RL
Gynecol Oncol; 2002 Feb; 84(2):289-95. PubMed ID: 11812089
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response.
Kunos C; Radivoyevitch T; Abdul-Karim FW; Faulhaber P
Int J Gynecol Cancer; 2011 Aug; 21(6):1117-23. PubMed ID: 21792015
[TBL] [Abstract][Full Text] [Related]
12. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer.
Schwarz JK; Siegel BA; Dehdashti F; Myerson RJ; Fleshman JW; Grigsby PW
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):180-6. PubMed ID: 17996387
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
14. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy.
Xue F; Lin LL; Dehdashti F; Miller TR; Siegel BA; Grigsby PW
Gynecol Oncol; 2006 Apr; 101(1):147-51. PubMed ID: 16263155
[TBL] [Abstract][Full Text] [Related]
15. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
[TBL] [Abstract][Full Text] [Related]
18. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.
Brooks RA; Rader JS; Dehdashti F; Mutch DG; Powell MA; Thaker PH; Siegel BA; Grigsby PW
Gynecol Oncol; 2009 Jan; 112(1):104-9. PubMed ID: 18929403
[TBL] [Abstract][Full Text] [Related]
19. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT.
Tsai CS; Chang TC; Lai CH; Tsai CC; Ng KK; Hsueh S; Yen TC; Hong JH
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1506-12. PubMed ID: 15050330
[TBL] [Abstract][Full Text] [Related]
20. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix.
Tran BN; Grigsby PW; Dehdashti F; Herzog TJ; Siegel BA
Gynecol Oncol; 2003 Sep; 90(3):572-6. PubMed ID: 13678726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
